Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung c (Q53065361)
Jump to navigation
Jump to search
scientific article published on 27 December 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung c |
scientific article published on 27 December 2013 |
Statements
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung c (English)
Joachim von Pawel
Jimmie H Harvey
David R Spigel
Mircea Dediu
Martin Reck
Cristina L Cebotaru
Robin C Humphreys
Matthew J Gribbin
Norma Lynn Fox
D Ross Camidge
27 December 2013
15
3
188-196.e2